Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference

Key Takeaways

• Precision will present at Needham conference April 14, 2026.
• ARCUS platform enables in vivo gene editing therapies.
• Pipeline includes HBV and DMD programs using ARCUS.
• Webcast live; replay posted on investor website.
• Investors can arrange meetings via Needham representatives.

Pulse Analysis

The Needham Healthcare Conference has become a bellwether for biotech investors seeking early insight into emerging therapeutic platforms. By securing a slot at the virtual event, Precision BioSciences positions itself alongside industry peers to highlight progress on its ARCUS® system, a proprietary gene‑editing tool that promises smaller, more precise cuts than competing nucleases. The conference’s digital format expands reach, allowing analysts worldwide to engage with Precision’s leadership in real time and review detailed pipeline updates.

ARCUS distinguishes itself through a compact protein architecture and a simplified delivery mechanism, enabling in‑vivo applications that were previously limited to ex‑vivo approaches. Precision’s pipeline leverages this advantage across high‑unmet‑need indications: the PBGENE‑HBV program aims to eradicate viral DNA reservoirs, while PBGENE‑DMD targets large gene deletions to restore functional dystrophin. These programs illustrate the platform’s versatility—ranging from gene elimination to precise excision and insertion—potentially delivering durable cures for genetic and infectious diseases that lack effective treatments.

For investors, the Needham presentation offers a rare opportunity to gauge execution risk and commercial timelines directly from the company’s executive team. Positive reception could accelerate capital inflows, support future financing rounds, and enhance collaborations with pharmaceutical partners eager to adopt ARCUS technology. As the gene‑editing market anticipates regulatory milestones, Precision’s visibility at a high‑profile investor forum underscores its ambition to become a leading player in next‑generation therapeutics.